[1] KIM JM, LIN C, STAVRE Z, et al. Osteoblast-Osteoclast Communication and Bone Homeostasis. Cells. 2020;9(9):2073.
[2] HASEGAWA T, KIKUTA J, SUDO T, et al. Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1. Nat Immunol. 2019;20(12):1631-1643.
[3] AMIN N, BOCCARDI V, TAGHIZADEH M, et al. Probiotics and bone disorders: the role of RANKL/RANK/OPG pathway. Aging Clin Exp Res. 2020;32(3):363-371.
[4] UDAGAWA N, KOIDE M, NAKAMURA M, et al. Osteoclast differentiation by RANKL and OPG signaling pathways. J Bone Miner Metab. 2021; 39(1):19-26.
[5] WU H, YANG S, XIAO J, et al. Facile synthesis of multi-functional nano-composites by precise loading of Cu2+ onto MgO nano-particles for enhanced osteoblast differentiation, inhibited osteoclast formation and effective bacterial killing. Mater Sci Eng C Mater Biol Appl. 2021; 130:112442.
[6] LI ZH, SI Y, XU G, et al. High-dose PMA with RANKL and MCSF induces THP‑1 cell differentiation into human functional osteoclasts in vitro. Mol Med Rep. 2017;16(6):8380-8384.
[7] MUN SH, PARK PSU, PARK-MIN KH. The M-CSF receptor in osteoclasts and beyond. Exp Mol Med. 2020;52(8):1239-1254.
[8] CHAI L, ZHOU K, WANG S, et al. Psoralen and Bakuchiol Ameliorate M-CSF Plus RANKL-Induced Osteoclast Differentiation and Bone Resorption Via Inhibition of AKT and AP-1 Pathways in Vitro. Cell Physiol Biochem. 2018;48(5):2123-2133.
[9] KIM B, LEE KY, PARK B. Icariin abrogates osteoclast formation through the regulation of the RANKL-mediated TRAF6/NF-κB/ERK signaling pathway in Raw264.7 cells. Phytomedicine. 2018;51:181-190.
[10] AVNET S, CHANO T, MASSA A, et al. Acid microenvironment promotes cell survival of human bone sarcoma through the activation of cIAP proteins and NF-κB pathway. Am J Cancer Res. 2019;9(6):1127-1144.
[11] YAO Z, LEI W, DUAN R, et al. RANKL cytokine enhances TNF-induced osteoclastogenesis independently of TNF receptor associated factor (TRAF) 6 by degrading TRAF3 in osteoclast precursors. J Biol Chem. 2017;292(24):10169-10179.
[12] DOU Y, TIAN X, ZHANG J, et al. Roles of TRAF6 in Central Nervous System. Curr Neuropharmacol. 2018;16(9):1306-1313.
[13] ZHOU L, SONG H, ZHANG Y, et al. Polyphyllin VII attenuated RANKL-induced osteoclast differentiation via inhibiting of TRAF6/c-Src/PI3K pathway and ROS production. BMC Musculoskelet Disord. 2020;21(1): 112-121.
[14] SCHIMMACK G, SCHORPP K, KUTZNER K, et al. YOD1/TRAF6 association balances p62-dependent IL-1 signaling to NF-κB. Elife. 2017;6:e22416.
[15] SWARNKAR G, CHEN TH, ARRA M, et al. NUMBL Interacts with TAK1, TRAF6 and NEMO to Negatively Regulate NF-κB Signaling During Osteoclastogenesis. Sci Rep. 2017;7(1):12600.
[16] AN Y, ZHANG H, WANG C, et al. Activation of ROS/MAPKs/NF-κB/NLRP3 and inhibition of efferocytosis in osteoclast-mediated diabetic osteoporosis. FASEB J. 2019;33(11):12515-12527.
[17] MITCHELL JP, CARMODY RJ. NF-κB and the Transcriptional Control of Inflammation. Int Rev Cell Mol Biol. 2018;335:41-84.
[18] LEE WS, YASUDA S, KONO M, et al. MicroRNA-9 ameliorates destructive arthritis through down-regulation of NF-κB1-RANKL pathway in fibroblast-like synoviocytes. Clin Immunol. 2020;212:108348.
[19] JIMI E, TAKAKURA N, HIURA F, et al. The Role of NF-κB in Physiological Bone Development and Inflammatory Bone Diseases: Is NF-κB Inhibition “Killing Two Birds with One Stone”?. Cells. 2019;8(12):1636.
[20] BAK SU, KIM S, HWANG HJ, et al. Heme oxygenase-1 (HO-1)/carbon monoxide (CO) axis suppresses RANKL-induced osteoclastic differentiation by inhibiting redox-sensitive NF-κB activation. BMB Rep. 2017;50(2):103-108.
[21] KIM I, KIM JH, KIM K, et al. The IRF2BP2-KLF2 axis regulates osteoclast and osteoblast differentiation. BMB Rep. 2019;52(7):469-474.
[22] TAKAKURA N, MATSUDA M, KHAN M, et al. A novel inhibitor of NF-κB-inducing kinase prevents bone loss by inhibiting osteoclastic bone resorption in ovariectomized mice. Bone. 2020;135:115316.
[23] PARK JH, LEE NK, LEE SY. Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation. Mol Cells. 2017;40(10):706-713.
[24] CHEN H, SHEN G, SHANG Q, et al. Plastrum testudinis extract suppresses osteoclast differentiation via the NF-κB signaling pathway and ameliorates senile osteoporosis. J Ethnopharmacol. 2021;276: 114195.
[25] ANGATA T. Siglecs that Associate with DAP12. Adv Exp Med Biol. 2020; 1204:215-230.
[26] MATSUBARA T, ADDISON WN, KOKABU S, et al. Characterization of unique functionalities in c-Src domains required for osteoclast podosome belt formation. J Biol Chem. 2021;296:100790.
[27] GYŐRI DS, MÓCSAI A. Osteoclast Signal Transduction During Bone Metastasis Formation. Front Cell Dev Biol. 2020;8:507-522.
[28] PARK JH, JEONG E, LIN J, et al. RACK1 interaction with c-Src is essential for osteoclast function. Exp Mol Med. 2019;51(7):1-9.
[29] ZHI X, FANG C, GU Y, et al. Guaiacol suppresses osteoclastogenesis by blocking interactions of RANK with TRAF6 and C-Src and inhibiting NF-κB, MAPK and AKT pathways. J Cell Mol Med. 2020;24(9):5122-5134.
[30] JEONG E, CHOI HK, PARK JH, et al.STAC2 negatively regulates osteoclast formation by targeting the RANK signaling complex. Cell Death Differ. 2018;25(8):1364-1374.
[31] WANG D, GU JH, FENG LL, et al. 1-α,25-dihydroxyvitamin D3 potentiates avian osteoclast activation by increasing the formation of zipper-like structure via Src/Rac1 signaling. Biochem Biophys Res Commun. 2018;501(2):576-583.
[32] WANG W, BAI J, ZHANG W, et al. Protective Effects of Punicalagin on Osteoporosis by Inhibiting Osteoclastogenesis and Inflammation via the NF-κB and MAPK Pathways. Front Pharmacol. 2020;11:696.
[33] YIN Z, ZHU W, WU Q, et al. Glycyrrhizic acid suppresses osteoclast differentiation and postmenopausal osteoporosis by modulating the NF-κB, ERK, and JNK signaling pathways. Eur J Pharmacol. 2019;859: 172550.
[34] XIAO L, ZHONG M, HUANG Y, et al. Puerarin alleviates osteoporosis in the ovariectomy-induced mice by suppressing osteoclastogenesis via inhibition of TRAF6/ROS-dependent MAPK/NF-κB signaling pathways. Aging (Albany NY). 2020;12(21):21706-21729.
[35] JEEVARATNAM K, SALVAGE SC, LI M, et al. Regulatory actions of 3’,5’-cyclic adenosine monophosphate on osteoclast function: possible roles of Epac-mediated signaling. Ann N Y Acad Sci. 2018;1433(1):18-28.
[36] SHABAN NZ, KENAWY MY, TAHA NA, et al. Cellulose Acetate Nanofibers: Incorporating Hydroxyapatite (HA), HA/Berberine or HA/Moghat Composites, as Scaffolds to Enhance In Vitro Osteoporotic Bone Regeneration. Polymers (Basel). 2021;13(23):4140.
[37] LOU Z, PENG Z, WANG B, et al. miR-142-5p promotes the osteoclast differentiation of bone marrow-derived macrophages via PTEN/PI3K/AKT/FoxO1 pathway. J Bone Miner Metab. 2019;37(5):815-824.
[38] YAN DY, TANG J, CHEN L, et al. Imperatorin promotes osteogenesis and suppresses osteoclast by activating AKT/GSK3 β/β-catenin pathways. J Cell Mol Med. 2020;24(3):2330-2341.
[39] KIM JM, LEE K, JEONG D. Selective regulation of osteoclast adhesion and spreading by PLCγ/PKCα-PKCδ/RhoA-Rac1 signaling. BMB Rep. 2018;51(5):230-235.
[40] JEONG DH, KWAK SC, LEE MS, et al. Betulinic Acid Inhibits RANKL-Induced Osteoclastogenesis via Attenuating AKT, NF-κB, and PLCγ2-Ca2+ Signaling and Prevents Inflammatory Bone Loss. J Nat Prod. 2020; 83(4):1174-1182.
[41] KAMANO Y, WATANABE J, IIDA T, et al. Binding of PICK1 PDZ domain with calcineurin B regulates osteoclast differentiation. Biochem Biophys Res Commun. 2018;496(1):83-88.
[42] WU L, LUO Z, LIU Y, et al. Aspirin inhibits RANKL-induced osteoclast differentiation in dendritic cells by suppressing NF-κB and NFATc1 activation. Stem Cell Res Ther. 2019;10(1):375.
[43] YU J, ZANOTTI S, SCHILLING L, et al. Nuclear factor of activated T cells 2 is required for osteoclast differentiation and function in vitro but not in vivo. J Cell Biochem. 2018;119(11):9334-9345.
[44] BAEK K, PARK HJ, BAEK JH, et al. Isoproterenol Increases RANKL Expression in a ATF4/NFATc1-Dependent Manner in Mouse Osteoblastic Cells. Int J Mol Sci. 2017;18(10):2204.
[45] MOGNOL GP, GONZÁLEZ-AVALOS E, GHOSH S, et al. Targeting the NFAT:AP-1 transcriptional complex on DNA with a small-molecule inhibitor. Proc Natl Acad Sci U S A. 2019;116(20):9959-9968.
[46] KATAGIRI T, KAMEDA H, NAKANO H, et al. Regulation of T cell differentiation by the AP-1 transcription factor JunB. Immunol Med. 2021;44(3):197-203.
[47] PANG M, RODRÍGUEZ-GONZALEZ M, HERNANDEZ M, et al. AP-1 and MITF interact with NFATc1 to stimulate cathepsin K promoter activity in osteoclast precursors. J Cell Biochem. 2019;120(8):12382-12392.
[48] JANG JS, KANG IS, CHA YN, et al. Vav1 inhibits RANKL-induced osteoclast differentiation and bone resorption. BMB Rep. 2019;52(11):659-664.
[49] REN X, ZHOU Q, FOULAD D, et al. Nanoparticulate mineralized collagen glycosaminoglycan materials directly and indirectly inhibit osteoclastogenesis and osteoclast activation. J Tissue Eng Regen Med. 2019;13(5):823-834.
[50] CAI X, XING J, LONG CL, et al. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis. J Bone Miner Res. 2017;32(11):2207-2218.
[51] KUROTAKI D, YOSHIDA H, TAMURA T. Epigenetic and transcriptional regulation of osteoclast differentiation. Bone. 2020;138:115471.
[52] KIM KT, LEE YS, HAN I. The Role of Epigenomics in Osteoporosis and Osteoporotic Vertebral Fracture. Int J Mol Sci. 2020;21(24):9455.
|